Table 1. Cytogenetic findings and... | American Society of Hematology

Table 1.

Cytogenetic findings and mutation characteristics of 14 patients with t-MNs

Patient ID	t-MN type	Cytogenetic findings	Gene	Amino acid change	VAF CHIP, %	VAF t-MN, %	Detected CNA in CHIP	Clonal fraction, %
UID12766	t-AML	Normal	WT1	p.S381X	ND	14.75	ND
UID984	t-MDS	46∼47,XY,+X,del(7)(q11.2),r(7),add(9)(q12)	ND		ND	ND	Chr 7 loss	18
UID10164	t-MDS	46, XX, +1, der(1;7)(q10;p10)	RUNX1	p.L98fs	3.69	23.27	ND
UID6982	t-AML	46, XY, del(5)(q15q33)	IDH2	p.R140Q	15.83	45.51	ND
			SRSF2	p.P95delinsRP	13.76	25.32
UID488	t-MDS	Normal	DNMT3A	p.R882P	19.93	33.14	ND
			IDH2	p.R172K	ND	15.46
UID36491	t-MDS	42, X, −Y, del(1)(q21), del(7)(q11.2q31), del(14)(q12q21), −16, −18, 21, −22, −22, +2mar[11], 44, X, −Y, del(1)(q21), del(7)(q11.2q31), del(14)(q12q21), −18, −21, +mar[5], 46, XY[4]	TP53	p.H193R	22.31	73.09	Chr 7 loss	14
							Chr 16 loss	12
							Chr 18 loss	18
UID4473	t-MDS	Normal	TET2	p.L1212X	5.29	45.34	ND
UID17285	t-MDS	45, XY, add(2)(p12), −5, −7, t(11;17)(q13;p11.2), +mar	TET2	p.Y1255X	8.45	18.06	ND
			TP53	p.Y205C	8.57	22.31
			U2AF1	p.Q157P	3.92	11.73
UID19684	t-MDS	46, XY, −7, +22	DNMT3A	p.R882C	18.85	47.06	Chr 7 loss	36
			NRAS	p.G13V	7.65	8.82	Chr 22 gain	26
			PTPN11	p.G60V	4.31	14.81
UID7393	t-AML	46, XY, del(5)(q13q33), 46, XY, der(3;5)(q10;p10), +8	KRAS	p.G12A	ND	10.28	ND
			NRAS	p.G13R	ND	17.1
			TP53	p.Y107X	0.92	97.16
UID49278	t-AML	45, X, −Y	FLT3	p.D593delinsEAPGEVD	0.98	22.45	ND
			GNB1	p.K57E	28.53	37.79
			KDM6A	p.R658X	1.19	72.12
			RAD21	p.E553X	ND	41.2
			RUNX1	p.G165fs	ND	20.66
			RUNX1	p.R204X	0.68	30.67
			SRSF2	p.P85H	36.92	33.58
UID12484	t-AML	45, XY, der(7;17)(p10;q10)	TP53	p.L194H	ND	41.97	ND
UID19304	t-MDS	46, XX, inv(3)(q21q26.2)	GATA2	p.Y322_M325delinsW	ND	33.7	ND
UID31000	t-AML	44, XY, del(5)(q13), add(7)(q11.2), −11, −12, −17, −17, +r, +mar	TET2	p.H1380Y	8.74	21.21	ND

Patient ID	t-MN type	Cytogenetic findings	Gene	Amino acid change	VAF CHIP, %	VAF t-MN, %	Detected CNA in CHIP	Clonal fraction, %
UID12766	t-AML	Normal	WT1	p.S381X	ND	14.75	ND
UID984	t-MDS	46∼47,XY,+X,del(7)(q11.2),r(7),add(9)(q12)	ND		ND	ND	Chr 7 loss	18
UID10164	t-MDS	46, XX, +1, der(1;7)(q10;p10)	RUNX1	p.L98fs	3.69	23.27	ND
UID6982	t-AML	46, XY, del(5)(q15q33)	IDH2	p.R140Q	15.83	45.51	ND
			SRSF2	p.P95delinsRP	13.76	25.32
UID488	t-MDS	Normal	DNMT3A	p.R882P	19.93	33.14	ND
			IDH2	p.R172K	ND	15.46
UID36491	t-MDS	42, X, −Y, del(1)(q21), del(7)(q11.2q31), del(14)(q12q21), −16, −18, 21, −22, −22, +2mar[11], 44, X, −Y, del(1)(q21), del(7)(q11.2q31), del(14)(q12q21), −18, −21, +mar[5], 46, XY[4]	TP53	p.H193R	22.31	73.09	Chr 7 loss	14
							Chr 16 loss	12
							Chr 18 loss	18
UID4473	t-MDS	Normal	TET2	p.L1212X	5.29	45.34	ND
UID17285	t-MDS	45, XY, add(2)(p12), −5, −7, t(11;17)(q13;p11.2), +mar	TET2	p.Y1255X	8.45	18.06	ND
			TP53	p.Y205C	8.57	22.31
			U2AF1	p.Q157P	3.92	11.73
UID19684	t-MDS	46, XY, −7, +22	DNMT3A	p.R882C	18.85	47.06	Chr 7 loss	36
			NRAS	p.G13V	7.65	8.82	Chr 22 gain	26
			PTPN11	p.G60V	4.31	14.81
UID7393	t-AML	46, XY, del(5)(q13q33), 46, XY, der(3;5)(q10;p10), +8	KRAS	p.G12A	ND	10.28	ND
			NRAS	p.G13R	ND	17.1
			TP53	p.Y107X	0.92	97.16
UID49278	t-AML	45, X, −Y	FLT3	p.D593delinsEAPGEVD	0.98	22.45	ND
			GNB1	p.K57E	28.53	37.79
			KDM6A	p.R658X	1.19	72.12
			RAD21	p.E553X	ND	41.2
			RUNX1	p.G165fs	ND	20.66
			RUNX1	p.R204X	0.68	30.67
			SRSF2	p.P85H	36.92	33.58
UID12484	t-AML	45, XY, der(7;17)(p10;q10)	TP53	p.L194H	ND	41.97	ND
UID19304	t-MDS	46, XX, inv(3)(q21q26.2)	GATA2	p.Y322_M325delinsW	ND	33.7	ND
UID31000	t-AML	44, XY, del(5)(q13), add(7)(q11.2), −11, −12, −17, −17, +r, +mar	TET2	p.H1380Y	8.74	21.21	ND

Chr, chromosome; ND, not detected; t-AML, therapy-related acute myeloid leukemia; t-MDS, therapy-related myelodysplastic syndrome.

View Large

This Feature Is Available To Subscribers Only